MX386503B - Medicamentos terapeuticos de matriz extracelular endotelial corneal. - Google Patents
Medicamentos terapeuticos de matriz extracelular endotelial corneal.Info
- Publication number
- MX386503B MX386503B MX2016001457A MX2016001457A MX386503B MX 386503 B MX386503 B MX 386503B MX 2016001457 A MX2016001457 A MX 2016001457A MX 2016001457 A MX2016001457 A MX 2016001457A MX 386503 B MX386503 B MX 386503B
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- corneal
- extracellular matrix
- corneal endothelial
- tgf
- Prior art date
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 210000002744 extracellular matrix Anatomy 0.000 title abstract 3
- 230000003511 endothelial effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 208000035475 disorder Diseases 0.000 abstract 4
- 206010010996 Corneal degeneration Diseases 0.000 abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
- 201000004781 bullous keratopathy Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
- 208000006069 Corneal Opacity Diseases 0.000 abstract 1
- 206010015958 Eye pain Diseases 0.000 abstract 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 abstract 1
- 206010020565 Hyperaemia Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010034960 Photophobia Diseases 0.000 abstract 1
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 abstract 1
- 206010047513 Vision blurred Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 231100000269 corneal opacity Toxicity 0.000 abstract 1
- 210000003683 corneal stroma Anatomy 0.000 abstract 1
- 210000000871 endothelium corneal Anatomy 0.000 abstract 1
- 230000004313 glare Effects 0.000 abstract 1
- 208000029257 vision disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona medicamentos para tratar o prevenir un padecimiento, trastorno, o condición que se asocia con la anormalidad de la matriz extracelular (ECM) en un endotelio corneal, en donde los medicamentos comprenden un agente de inhibición de la señal del TGF-beta; más específicamente, este padecimiento, trastorno, o condición es un trastorno asociado con la distrofia corneal endotelial de Fuchs; tal trastorno incluye fotofobia, visión borrosa, trastorno de visión, dolor de ojos, lagrimeo, hiperemia, dolor, queratopatía bullosa, molestia oftálmica, una disminución en el contraste, deslumbramiento, edema en el estroma corneal, queratopatía bullosa, opacidad corneal, y similares; un agente de inhibición de la señal del TGF-beta preferible incluye 4-[4-(1,3-benzodioxol-5-il)-5-(2-piridinil)-1H-imidazol-2-il]benzamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2013/071095 WO2015015654A1 (ja) | 2013-07-30 | 2013-07-30 | 角膜内皮ｅｃｍ治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001457A MX2016001457A (es) | 2016-11-11 |
| MX386503B true MX386503B (es) | 2025-03-19 |
Family
ID=52431224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001457A MX386503B (es) | 2013-07-30 | 2013-07-30 | Medicamentos terapeuticos de matriz extracelular endotelial corneal. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11730722B2 (es) |
| JP (1) | JP6403217B2 (es) |
| BR (1) | BR112016002015A2 (es) |
| CA (1) | CA2919316C (es) |
| MX (1) | MX386503B (es) |
| RU (1) | RU2016106641A (es) |
| WO (1) | WO2015015654A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386503B (es) | 2013-07-30 | 2025-03-19 | Kyoto Prefectural Public Univ Corp | Medicamentos terapeuticos de matriz extracelular endotelial corneal. |
| CA2927898C (en) * | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| US20200386744A1 (en) * | 2017-06-16 | 2020-12-10 | The Doshisha | Novel screening method for tgf-beta inhibitor |
| JP7398729B2 (ja) | 2017-12-13 | 2023-12-15 | 学校法人同志社 | （ｔ）ｅｗ－７１９７を含む角膜内皮疾患を治療または予防するための組成物または方法 |
| JP7542799B2 (ja) * | 2018-07-04 | 2024-09-02 | 京都府公立大学法人 | 眼組織の線維化抑制用組成物 |
| EP4110465A4 (en) * | 2020-02-24 | 2024-06-12 | The Board Of Regents Of The University Of Texas System | BIOMARKERS AND MOLECULAR TARGETS FOR FUCHS CORNEAL ENDOTHELIAL DYSTROPHY AND GLAUCOMA |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703047A (en) * | 1992-09-21 | 1997-12-30 | Board Of Regents, The University Of Texas System | Methods and treatments for corneal healing with growth factors |
| AU5593398A (en) * | 1996-12-05 | 1998-06-29 | Alcon Laboratories, Inc. | The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| JP2003512433A (ja) | 1999-10-29 | 2003-04-02 | バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー | 角膜欠陥を処置するためのｇｄｎｆの使用 |
| CA2404915A1 (en) * | 2000-04-07 | 2001-10-18 | Sang Geon Kim | Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz |
| EP1511738A4 (en) | 2002-05-17 | 2007-05-09 | Scios Inc | TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS |
| AU2003257666A1 (en) | 2002-08-23 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| US8158589B2 (en) | 2003-08-22 | 2012-04-17 | Proyecto Biomedicine Cima, S.L. | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) |
| JP2008513465A (ja) | 2004-09-15 | 2008-05-01 | ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ | 肥満及び糖尿病の治療におけるｅｒストレス低減 |
| WO2006086452A1 (en) | 2005-02-10 | 2006-08-17 | Regents Of The University Of Minnesota | Methods for treating visual disorders |
| KR100657935B1 (ko) * | 2005-03-08 | 2006-12-14 | 메디제네스(주) | ＴＧＦ－β에 대한 항체를 포함하는 아벨리노각막이영양증의 치료용 약학 조성물 |
| BRPI0619966A2 (pt) | 2005-12-16 | 2011-10-25 | Alcon Inc | controle de pressão intra-ocular usando agentes de modulação de alk5 |
| US8946201B2 (en) | 2007-08-27 | 2015-02-03 | Saint Louis University | Methods for inhibiting TGF-β |
| WO2009146408A1 (en) | 2008-05-30 | 2009-12-03 | Summa Health Systems Llc | Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions |
| US20100267731A1 (en) * | 2009-04-17 | 2010-10-21 | Summa Health Systems, LLC | Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring |
| US20130288985A1 (en) * | 2010-07-15 | 2013-10-31 | The Schepens Eye Research Institute Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| KR101258166B1 (ko) | 2010-09-01 | 2013-04-25 | 연세대학교 산학협력단 | Ｔｇｆｂｉ 유전자 변이 각막 이상증의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법 |
| US9574171B2 (en) | 2010-12-02 | 2017-02-21 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
| PL2788472T3 (pl) | 2011-12-06 | 2019-06-28 | Astellas Institute For Regenerative Medicine | Sposób ukierunkowanego różnicowania z wytwarzaniem komórek śródbłonka rogówki |
| ES2917222T3 (es) | 2011-12-28 | 2022-07-07 | Kyoto Prefectural Public Univ Corp | Normalización del cultivo de células endoteliales de la córnea |
| MX386503B (es) | 2013-07-30 | 2025-03-19 | Kyoto Prefectural Public Univ Corp | Medicamentos terapeuticos de matriz extracelular endotelial corneal. |
| CA2927898C (en) | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
-
2013
- 2013-07-30 MX MX2016001457A patent/MX386503B/es unknown
- 2013-07-30 WO PCT/JP2013/071095 patent/WO2015015654A1/ja not_active Ceased
- 2013-07-30 US US14/907,881 patent/US11730722B2/en active Active
- 2013-07-30 BR BR112016002015A patent/BR112016002015A2/pt not_active Application Discontinuation
- 2013-07-30 CA CA2919316A patent/CA2919316C/en active Active
- 2013-07-30 RU RU2016106641A patent/RU2016106641A/ru unknown
- 2013-07-30 JP JP2015529317A patent/JP6403217B2/ja active Active
-
2023
- 2023-06-07 US US18/330,510 patent/US20230310402A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2015015654A1 (ja) | 2017-03-02 |
| CA2919316A1 (en) | 2015-02-05 |
| US20160158210A1 (en) | 2016-06-09 |
| BR112016002015A2 (pt) | 2017-08-01 |
| JP6403217B2 (ja) | 2018-10-10 |
| RU2016106641A (ru) | 2017-09-01 |
| MX2016001457A (es) | 2016-11-11 |
| CA2919316C (en) | 2021-08-10 |
| US11730722B2 (en) | 2023-08-22 |
| WO2015015654A1 (ja) | 2015-02-05 |
| US20230310402A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386503B (es) | Medicamentos terapeuticos de matriz extracelular endotelial corneal. | |
| MX2019002861A (es) | Composicion farmaceutica. | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| DOP2017000270A (es) | Composiciones farmacéuticas tópicas | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| WO2017158366A3 (en) | Ophthalmic delivery device and ophthalmic drug compositions | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| AR103130A1 (es) | Sonda de vitrectomía con un escáner de fibra óptica | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
| MX2016005680A (es) | Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea. | |
| BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| FI3811943T3 (fi) | Yhdiste käytettäväksi silmäsairauksien hoidossa | |
| CL2018000002A1 (es) | Agente terapéutico y método para tratar el síndrome de hunter. | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| BR112013017875A2 (pt) | introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas | |
| MX2017009037A (es) | Compuestos espiro triciclicos. | |
| MX355853B (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| BR112022008282A2 (pt) | Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo | |
| BR112019024878A2 (pt) | Agente para prevenção ou tratamento de tauopatia | |
| UY31786A1 (es) | Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos oculares | |
| BR112018007374A2 (pt) | composição farmacêutica | |
| BR112017021374A2 (pt) | ácido pirrolidona carboxílico (pca) para uso oftálmico |